

## 1.0.7 DOC EIA

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## NICE guidelines

### Equality impact assessment

## Heavy Menstrual Bleeding: assessment and management (update)

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

### 4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No additional potential equality issues were raised during consultation.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, there are no such recommendations.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, there is no potential for this.

## 1.0.7 DOC EIA

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.1, 4.2 and 4.3, or otherwise fulfil NICE's obligations to advance equality?

Not applicable.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

The Committee made a new recommendation stating that whether the woman wants to retain her fertility and her uterus should be included in the discussion of possible treatment options. The reasons for making this recommendation are discussed in the rationale and impact section and the committee's discussion of the evidence (management chapter).

Updated by Developer: Paul Jacklin, Guideline Lead

Date: 17<sup>th</sup> October 2017

Approved by NICE quality assurance lead: Christine Carson

Date: 13/03/2018